The article reports on the successful financial investment of BioXell on the Swiss Exchange SWX in Italy. The initial public offering (IPO) is intended for the development of the biotechnological and life sciences research that is conforming to the booming of the commercial industry. Furthemore, IPO grossly amounted to $46.9 million, that is believed to offer significant help in strengthening the biotech sector in the country.